LEO Pharma has shared final results from a long-term extension study of its atopic dermatitis (AD) drug Adbry ...

Merck & Co – known as MSD outside the US and Canada – has acquired Yale University oncology spinout Modifi Biosciences in a ...

Dermavant previously reported positive results from the identically-designed phase 3 ADORING 1 and ADORING 2 trials, which ...

Novartis’ Kisqali (ribociclib) has been recommended by the European Medicines Agency’s human medicines committee to reduce the risk of recurrence in early breast cancer patients. The Committee for ...

This blog will discuss some important aspects to consider to maximise patient retention on your flu clinical trials. For more ...

Merck & Co’s – known as MSD outside the US and Canada – Keytruda (pembrolizumab) has been recommended by the National Institute of Health and Care Excellence (NICE) to treat resectable non-small cell ...

AbbVie has announced that it will be acquiring Aliada Therapeutics for $1.4bn, marking a notable boost to its neuroscience pipeline. The deal gives AbbVie access to Aliada’s therapies that use a novel ...

Johnson & Johnson (J&J) has shared positive results from a late-stage study of its dual-acting IL-23 inhibitor Tremfya (guselkumab) in plaque psoriasis patients. The phase 3b SPECTREM trial has been ...

The healthcare communications industry is in ‘re-set’ mode. Challenges with resourcing and budgets mean in-house and agency teams must work harder and more collaboratively than ever to demonstrate ...

Johnson & Johnson (J&J) has announced that a subcutaneous (SC) formulation of Darzalex (daratumumab) has been approved by the European Commission (EC) as part of a combination treatment for newly ...

After the recent Paralympics, I can’t help but be in awe of the individuals who participated and achieved such amazing feats, despite having everyday challenges most of us can hardly comprehend. It is ...

Susanne Bobadilla from VML Health, joined by a team of 15 medical, digital strategists and client engagement experts from across the company, looks at the top trends coming out of ESMO 2024 and what ...